Description: POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.
Home Page: www.pointbiopharma.com
PNT Technical Analysis
4850 West 78th Street
Indianapolis,
IN
46268
United States
Phone:
647 812 2417
Officers
| Name | Title |
|---|---|
| Mr. Allan Charles Silber | Exec. Chairman |
| Dr. Joe A. McCann Ph.D. | CEO & Director |
| Dr. Neil E. Fleshner FRCSC, M.D., M.PH | Chief Medical Officer & Director |
| Ms. Jessica D. Jensen M.P.H., MPH | Exec. VP of Clinical Devel. |
| Mr. Bill Demers B.B.A., F.C.A., FCPA | Chief Financial Officer |
| Ms. Justyna Kelly M.Sc. | Chief Operating Officer |
| Ms. Donna Husack B.A. | VP of HR |
| Mr. Ari Shomair | VP of Corp. Affairs & Chief of Staff |
| Dr. Myra Rosario Herle Ph.D., R.Ph. | Exec. VP of Regulatory Affairs |
| Dr. Matthew P. Vincent J.D., Ph.D. | Sr. VP of Bus. Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 62.8931 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2559 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-07-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 72 |